- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
NICE recommends adalimumab for hidradenitis suppurativa
6 May 2016 • Author: Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Humira (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS) in adult patients with an inadequate response to conventional systemic HS therapy.
Adalimumab, the first treatment option licensed for active moderate to severe HS, can help reduce the number of total inflammatory nodules and abscesses that appear by at least 50 percent, as well as reduce skin pain by a third.
Commenting on the recommendation, Dr David Fitzgerald, consultant dermatologist at Salford Royal NHS Foundation Trust said: “Adalimumab is the only licensed treatment for HS so I’m pleased that NICE has now recommended its use so that patients across England and Wales should be able to receive it. People with HS experience frequent painful lesions, often accompanied by discharge, which can have a devastating effect on quality of life, so a treatment that can reduce the frequency of these episodes and the severity of the pain is a great asset in an area where options are currently very limited.”
Not much is known about HS and it is frequently mistaken for other conditions, including acne or a simple infection. This can lead to a lengthy delay in diagnosis and treatment.
“A very important step” for HS patients
Tara Burton, HS patient and founder of patient advocacy organisation the HS Trust, said: “HS can be a disabling condition, making it difficult or even impossible for people to do the simplest of things. It can detrimentally affect mobility, personal care, physical and emotional well-being. Increasing awareness of HS and its impact on patients will help earlier recognition of the condition, and hopefully enable people living with HS to get their condition under control. New treatments play a part in helping people to manage this condition.”
Alice Butler, Medical Director, AbbVie UK, commented: “Today’s recommendation marks a very important step for patients with HS who can often suffer painful, difficult-to-heal symptoms. We are extremely pleased that healthcare professionals will be able to offer more options, outside of traditional treatments which include antibiotics and steroids, to help patients manage their HS symptoms which can often be mistaken for other skin conditions.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics